Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy - Chamberlain, C A; Bennett, E P; Kverneland, A H (Molecular Therapy - Oncolytics, 2022)